Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Health Costs and Resource Utilization

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males 18 years of age or older who are not receiving azathioprine or 6 mercaptopurine.~* Non-pregnant, non-lactating females, 18 years of age or older.~* Females of child bearing potential must have a negative serum pregnancy test prior to randomization, and must use a hormonal (oral, implantable or injectable) or barrier method of birth control throughout the study. \[defined as a minimum of one year since the last menstrual period\]).~* Documented diagnosis of CD or UC.~* Active disease symptoms at visit 1 defined by: a. CD subjects: HBS \~ 6 UC subjects: PMCS \~ 4.~* Current infliximab therapy (naive to adalimumab) or current adalimumab therapy (naive to infliximab ).~* A minimum of 13 weeks of infliximab or adalimumab treatment prior to visit 1 at the following dose:~* Stable dose of azathioprine, 6 mercaptopurine, methotrexate, and/or 5-aminosalicylates in the 4 weeks prior to visit 1.~Exclusion Criteria:~* Contraindication to the use of either infliximab or adalimumab.~* Current infliximab treatment but not naive to adalimumab or~* Current adalimumab treatment but not naive to infliximab.~* Infliximab dosing prior to visit 1 was not 5 mg/kg at weeks 0, 2 and 6 and then q8w.~* Adalimumab dosing prior to visit 1 was not 160 mg at week 0, 80 mg at week 2, and then 40 mg q2w.~* Received any investigational drug within 30 days prior to visit 1.~* Serious underlying disease other than CD or UC which in the opinion of the investigator may interfere with the subject's ability to participate fully in the study.~* History of alcohol or drug abuse which in the opinion of the investigator may interfere with the subject's ability to comply with the study procedures.~* Stools positive for clostridium difficile.~* Pregnant or lactating women.~* Change in dose of azathioprine, 6 mercaptopurine, methotrexate, and/or 5-aminosalicylates in the 4 weeks prior to visit 1.~* Males 22 years of age or less who are receiving azathioprine or 6 mercaptopurine.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Empiric Dose Intensification (Type: ACTIVE_COMPARATOR): Intensify treatment with the existing drug
- Testing based strategy (Type: ACTIVE_COMPARATOR): Measurement of drug (Adalimumab/Infliximab) Testing-based strategy for the management of secondary loss of response that is based on drug/ ADA measurement

Based on this trial design, predict the completion outcome and termination type (if applicable).